ClinicalTrials.gg
CompletedNCT00448942Updated Mar 19, 2007

The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections

An observational study in Nosocomial Bacteremia, Nosocomial Fungemia and MRSA Colonization, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-03-19.

Sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center · Observational

Study type
Observational
Model
Defined population
Time perspective
Retrospective
Enrollment
5,300
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to determine if the use of daily chlorhexidine bathing would decrease the incidence of MRSA and VRE colonization and healthcare associated Bloodstream Infections (BSI) among Intensive Care Unit (ICU) patients.

Read the detailed description

Infections due to Staphylococci including MRSA are the predominant nosocomially acquired complication in the intensive care unit. The increasing incidence of MRSA colonization and infection among ICU patients has been attributed to many factors including increased admission of patients already colonized with MRSA to the ICU, poor compliance with handwashing and barrier precautions, delayed identification of MRSA colonized patients, and understaffing. Measures that have proven to limit horizontal transmission between patients and staff and staff to patients include strict attention to barrier precautions and handwashing. Unfortunately both of these strategies require levels of compliance that are often not achieved.

Nosocomial blood stream infections are a leading source of morbidity and mortality among intensive care unit patients. Several modifiable factors have been shown to increase the risk of bloodstream infections. These include lapses in the use of strict sterile technique in the insertion of central venous catheters and improper site preparation. New CDC guidelines on the prevention of catheter related bloodstream infections recommend that the preferential use of chlorhexidine containing skin disinfectants be used for site preparation prior to insertion. The use of chlorhexidine reduces residual skin organisms as well as inhibits their rebound growth and has been demonstrated to reduce catheter-associated bloodstream infections in comparison to other skin disinfectant products such as povidone-iodine.

As a result of guidelines promoting the use of chlorhexidine, a number of intensive care units have implemented quality improvement projects examining the potential role of chlorhexidine based bathing of intensive care unit patients in reducing nosocomial transmission of multiresisitant organisms such as MRSA and vancomycin-resistant enterocooci (VRE). The goal of the currently proposed study is to analyse existing data from participating intensive care units that have adopted the use of chlorhexidine antisepsis to determine the impact of chlorhexidine on bacterial colonization and nosocomial infections Participating hospitals who have completed quality improvement projects that included the use of chlorhexidine in bathing of ICU patients will submit de-identified data on nosocomial bacteremias and MRSA and VRE colonization during defined time periods where chlorhexidine bathing was used in comparison to time periods where regular bathing procedures were utilized.

02

Conditions studied

  • Nosocomial Bacteremia
  • Nosocomial Fungemia
  • MRSA Colonization
  • MRSA Infection
  • VRE Colonization
  • VRE Infection

Browse trials for

Keywords

  • Staphylococcus aureus [B03.510.400.790.750.100]
  • Enterococcus faecalis [B03.510.400.800.280.280]
  • Enterococcus faecium [B03.510.400.800.280.300]
  • Bacteremia [C01.252.100]
  • Fungemia [C01.703.360]
  • Infection Control [G03.850.780.200.450]
  • Antisepsis [G03.850.780.200.450.150]
03

In context

Bacteremia

297 studies on the registry are indexed under Bacteremia; 51 are open to participants now.

This study's enrollment of 5,300 is above the median of 300 across 125 observational studies indexed under Bacteremia.

Browse Bacteremia studies →

Lead sponsor

Hunter Holmes Mcguire Veteran Affairs Medical Center is the lead sponsor of 31 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult patients admitted to study units

Exclusion criteria

Exclusion Criteria:

  • Children under the age of 18
  • Previous adverse reaction or documented allergy to chlorhexidine based products
05

Study design

Observational model
Defined population
Time perspective
Retrospective
Enrollment
5,300 participants

Interventions

  • BehavioralDaily bathing with Chlorhexidine based product
06

Study locations

4 sites
  • Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
  • Barnes Jewish Hospital
    St. Louis, Missouri 63110, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • Hunter Holmes McGuire Veteran Affairs Medical Center
    Richmond, Virginia 23249, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00448942
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
First posted
Mar 19, 2007
Start date
Nov 2004
Completion
Jan 2006
Last update
Mar 19, 2007

Study contacts

Edward W Wong, MD
principal investigator · Hunter Holmes Mcguire Veteran Affairs Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion